An RCT in 103 CTCL patients comparing TSEB and multi-agent chemotherapy (CAVE) with sequential topical therapy including superficial radiotherapy and phototherapy revealed a higher CR rate in the TSEB/chemotherapy group (38% compared with 18%; P= 0-032) but after a median follow up of 75 months DFS and OS did not differ significantly.77
A retrospective non-randomised study comparing TSEB (32-40 Gy) alone with TSEB followed by
ECP (given 2 days monthly for a median of 6 months) in 44 patients with erythrodermic CTCL (57% stage III, 30% stage IVA, 13% stage IVB/overall 59% had haematological involvement B1) has reported an overall CR rate of 73% after TSEB, with a 3-year DFS of 49% for 17 patients who received only TSEB (OS 63%) and 81% for 15 patients who received TSEB followed by ECP (OS 88%).78 A multivariate analysis suggested that the combination of TSEB and ECP was significantly associated with a prolonged disease-free and cause-specific survival when corrected for peripheral blood involvement (B1) and stage of disease.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.